acquired
Stage
About
Disarm Therapeutics develops therapeutics targeting neurodegenerative diseases by focusing on mitigating axonal degeneration.
Explore Disarm Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.